Literature DB >> 3627181

Circulating erythroid progenitors in the anemia of prematurity.

K M Shannon, G S Naylor, J C Torkildson, G K Clemons, V Schaffner, S L Goldman, K Lewis, P Bryant, R Phibbs.   

Abstract

We studied erythropoiesis in infants with the anemia of prematurity by counting the number of colonies derived from erythroid burst-forming units (BFU-E) in the blood of 11 premature infants before they received transfusions. Colony growth in blood from the infants was compared with growth in blood from adults and umbilical-cord blood from term infants, in the presence of erythropoietin, 0 to 2000 mU per milliliter. Addition of increasing concentrations of erythropoietin resulted in a stepwise increase in the number of colonies derived from BFU-E (P less than 0.0005) of all three groups of subjects. Cultures stimulated with 2000 mU of erythropoietin yielded 28.1 +/- 7.6, 88.0 +/- 19.4, and 121.0 +/- 22.5 bursts (mean +/- SE) per 10(5) cells plated in blood from adults, blood from premature infants, and cord blood, respectively. Although more BFU-E-derived colonies appeared when 200 or 2000 mU were present per milliliter in cultures of the infants' blood and cord blood, the intrinsic responsiveness of BFU-E to erythropoietin was similar in all groups. Although the mean hematocrit was 26 percent, mean serum erythropoietin concentrations (+/- SD) in the infants (20.7 +/- 10.0 mU per milliliter) were not significantly different from those in the adult controls (24.0 +/- 6.5). We conclude that progenitor cells committed to erythroid differentiation are present during the anemia of prematurity, and that the intrinsic responsiveness of the circulating BFU-E pool to erythropoietin is normal. These results implicate inadequate production of erythropoietin as the cause of the anemia of prematurity and suggest that recombinant erythropoietin might provide a therapeutic alternative to transfusion for symptomatic babies with this condition.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3627181     DOI: 10.1056/NEJM198709173171203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  16 in total

1.  Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary?

Authors:  A R Franz; F Pohlandt
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-03       Impact factor: 5.747

2.  Erythropoietic progenitor cells from premature neonates studied using a validated serum-deprived medium. Evidence that peripheral blood BFU-E from premature neonates are increased in number and are highly dependent upon burst promoting activity for in vitro growth.

Authors:  N B Westwood; A J Emmerson
Journal:  Cytotechnology       Date:  1991-07       Impact factor: 2.058

3.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

Review 4.  Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity.

Authors:  Robin K Ohls
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Role of erythropoietin in the newborn.

Authors:  A J Emmerson
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

6.  Double blind trial of recombinant human erythropoietin in preterm infants.

Authors:  A J Emmerson; H J Coles; C M Stern; T C Pearson
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

7.  Weekly intravenous administration of recombinant human erythropoietin in infants with the anaemia of prematurity.

Authors:  D Beck; E Masserey; M Meyer; A Calame
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

8.  Interleukin-3, interleukin-6, granulocyte-macrophage colony-stimulating factor and erythropoietin cord blood levels of preterm and term neonates.

Authors:  B Meister; M Herold; A Mayr; M Widschwendter; H Maurer; K Heim; W Sperl
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

9.  Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity.

Authors:  A G Bechensteen; P Hågå; S Halvorsen; A Whitelaw; K Liestøl; R Lindemann; J Grøgaard; M Hellebostad; O D Saugstad; M Grønn
Journal:  Arch Dis Child       Date:  1993-07       Impact factor: 3.791

10.  Recombinant human erythropoietin in the treatment of infants with anaemia of prematurity.

Authors:  D S Halpérin; M Félix; P Wacker; G Lacourt; J F Babel; M Wyss
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.